Vrise Therapeutics Inc. has discovered ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Erasca Inc. has described GTPase KRAS (G12D mutant) and/or KRAS (G12V mutant) inhibitors reported to be useful for the treatment of cancer.

Flare Therapeutics Inc. has disclosed cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

Bristol Myers Squibb Co. has prepared and tested proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety through a linker reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.

1200 Pharma LLC has synthesized GTPase KRAS (G12D mutant) degradation inducers reported to be useful for the treatment of cancer.

Nanjing Gentai Pharmaceutical Technology Co. Ltd. has divulged dual inhibitors of poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) and serine/threonine-protein kinase ULK1 reported to be useful for the treatment of cancer.

Muna Therapeutics ApS has patented triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes and more.

Chengdu Huajian Science Co. Ltd. has patented aromatic hydrazide derivatives reported to be useful for the treatment of cancer.

Beijing Tide Pharmaceutical Co. Ltd. has divulged nanobody-drug conjugates comprising a nanobody targeting B7 homolog 3 (B7-H3, CD276) covalently bound to exatecan through a linker reported to be useful for the treatment of lung cancer.

Primelink Biotherapeutics (Shenzhen) Co. Ltd. has discovered molecular glue degraders acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer.